Novel Science.
Expert Leadership.

Jasper Therapeutics’ management team is comprised of experienced biopharma industry veterans with extensive track records in drug development and commercialization. With this leadership, we are well positioned to achieve our vision of exponentially expanding the eligible patient population both for allogeneic and autologous gene edited hematopoietic stem cell therapy.

Management Team

Bill Lis

Executive Chairman and CEO

Jeet Mahal

Chief Financial and Business Officer

Kevin Heller, M.D.

Executive Vice President, Research and Development

Carol Zoltowski, V.M.D.

Senior Vice President, Regulatory Affairs and Quality

Luca Di Noto, Ph.D.

Vice President, Technical Operations

Wendy Pang, M.D., Ph.D.

Vice President, Research and Translational Medicine

Craig F. Burns, PhD, MS

Vice President, Program Management

Arjun Agarwal, CPA

Vice President, Finance and Corporate Controller

Board Of Directors

Judith Shizuru, M.D., Ph.D.

Bill Lis

Kurt von Emster

Anna French, Ph.D.

Lawrence Klein, Ph.D.

Chris Nolet

Scientific Advisory Board

Jasper Therapeutics has established a premier, world-class Scientific Advisory Board of accomplished scientific leaders who are experts in immunology, blood and bone marrow transplantation, stem cell and gene therapy, and hematologic cancers.

Judith Shizuru, M.D., Ph.D.

Art Weiss, M.D., Ph.D.

Fred Appelbaum, M.D.

Jeffrey Ravetch, M.D., Ph.D.

Lori Kunkel, M.D.